Esophageal Motility Disorders and Electrolyte Abnormalities

Pathophysiological Relationship

Magnesium deficiency causes dysfunction of multiple potassium transport systems, increasing renal potassium excretion, making hypokalemia resistant to treatment until hypomagnesemia is corrected 1
Hypokalemia with or without additional hypomagnesemia can prolong the QT interval, potentially leading to an increased risk of ventricular arrhythmias, which may further complicate esophageal motility disorders 2

High-resolution manometry (HRM) studies in patients with electrolyte abnormalities may show a variety of motility patterns, ranging from non-specific and normal, to hypotensive and ineffective motility as well as obstructive features 3

Acid regurgitation and chronic vomiting associated with esophageal motility disorders can lead to significant fluid losses, causing volume depletion and secondary hyperaldosteronism 1
Secondary hyperaldosteronism increases renal excretion of both potassium and magnesium, creating a vicious cycle where the motility disorder worsens electrolyte abnormalities 1

Serum magnesium levels should be checked in patients with unexplained hypokalemia, as serum levels don't accurately reflect total body magnesium status 1
Oesophageal physiological testing should be considered in patients with ongoing dysphagia despite treatment 4

Correcting fluid and sodium status is the first step in addressing secondary hyperaldosteronism, which can worsen both magnesium and potassium losses 1
Magnesium supplementation should be administered before or simultaneously with potassium to effectively correct hypokalemia 1
For severe magnesium deficiency, intravenous magnesium (1-2g IV over 15 minutes) may be necessary 1

Failing to check magnesium levels in patients with unexplained or refractory hypokalemia 1
Ignoring cardiac monitoring in patients with severe electrolyte disturbances, which can lead to life-threatening arrhythmias 1
Administering potassium supplementation without first correcting magnesium deficiency, as hypokalemia will be resistant to treatment 1
Overlooking the functional pathophysiology of symptoms in esophageal motility disorders, with the emphasis primarily on histology and endoscopic appearances 3

Patients on continuous kidney replacement therapy (CKRT) are at high risk for developing hypomagnesemia, especially when regional citrate anticoagulation is used 5
Dialysis solutions containing magnesium, along with potassium and phosphate, should be used to prevent electrolyte disorders during CKRT 5
Patients with Bartter syndrome may have both hypokalemia and hypomagnesemia, which can affect esophageal motility 2
Medications like proton-pump inhibitors, macrolides, fluoroquinolones, and diuretics can exacerbate hypomagnesemia and should be used with caution in patients with esophageal motility disorders 2